TriSalus Launches PREDICTT Trial to Optimize Liver Tumor Drug Delivery

Event summary

  • TriSalus Life Sciences has initiated patient enrollment for the PREDICTT clinical trial (NCT07444645) evaluating its Pressure-Enabled Drug Delivery™ (PEDD™) approach in liver tumors.
  • The trial will enroll approximately 20 adult patients with unresectable primary or metastatic liver tumors eligible for Y90 radioembolization.
  • The study aims to assess how PEDD impacts tumor targeting and radiation dose distribution using the TriNav® Infusion System.
  • The trial is led by principal investigator Peiman Habibollahi, M.D., at The University of Texas MD Anderson Cancer Center.

The big picture

TriSalus' PREDICTT trial addresses a critical challenge in liver tumor treatment: optimizing drug delivery to maximize tumor dose while minimizing exposure to healthy tissue. This aligns with broader industry trends toward precision oncology and the integration of advanced delivery technologies with standard therapies. The trial's success could redefine the delivery of Y90 therapies, potentially expanding TriSalus' market position in oncology.

What we're watching

Clinical Efficacy
Whether the PEDD approach can demonstrate superior tumor targeting and radiation dose distribution compared to standard Y90 radioembolization.
Regulatory Pathway
The pace at which TriSalus can translate positive trial results into regulatory approvals and commercial adoption.
Strategic Partnerships
How the collaboration with UT MD Anderson will influence future clinical and commercial strategies.

Related topics

Biotechnology